Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 1998 Apr-Jun;4(2):195–209. doi: 10.3201/eid0402.980207

Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.

A Rattan 1, A Kalia 1, N Ahmad 1
PMCID: PMC2640153  PMID: 9621190

Abstract

Multidrug-resistant strains of Mycobacterium tuberculosis seriously threaten tuberculosis (TB) control and prevention efforts. Molecular studies of the mechanism of action of antitubercular drugs have elucidated the genetic basis of drug resistance in M. tuberculosis. Drug resistance in M. tuberculosis is attributed primarily to the accumulation of mutations in the drug target genes; these mutations lead either to an altered target (e.g., RNA polymerase and catalase-peroxidase in rifampicin and isoniazid resistance, respectively) or to a change in titration of the drug (e.g., InhA in isoniazid resistance). Development of specific mechanism-based inhibitors and techniques to rapidly detect multidrug resistance will require further studies addressing the drug and drug-target interaction.

Full Text

The Full Text of this article is available as a PDF (514.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altamirano M., Marostenmaki J., Wong A., FitzGerald M., Black W. A., Smith J. A. Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis. 1994 May;169(5):1162–1165. doi: 10.1093/infdis/169.5.1162. [DOI] [PubMed] [Google Scholar]
  2. Banerjee A., Dubnau E., Quemard A., Balasubramanian V., Um K. S., Wilson T., Collins D., de Lisle G., Jacobs W. R., Jr inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994 Jan 14;263(5144):227–230. doi: 10.1126/science.8284673. [DOI] [PubMed] [Google Scholar]
  3. Barnes P. F., Bloch A. B., Davidson P. T., Snider D. E., Jr Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1991 Jun 6;324(23):1644–1650. doi: 10.1056/NEJM199106063242307. [DOI] [PubMed] [Google Scholar]
  4. Belanger A. E., Besra G. S., Ford M. E., Mikusová K., Belisle J. T., Brennan P. J., Inamine J. M. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11919–11924. doi: 10.1073/pnas.93.21.11919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bell R. T. Tuberculosis of the 1990s: the quiet public health threat. Pa Med. 1992 Mar;95(3):24–25. [PubMed] [Google Scholar]
  6. Benveniste R., Davies J. Mechanisms of antibiotic resistance in bacteria. Annu Rev Biochem. 1973;42:471–506. doi: 10.1146/annurev.bi.42.070173.002351. [DOI] [PubMed] [Google Scholar]
  7. Bergler H., Wallner P., Ebeling A., Leitinger B., Fuchsbichler S., Aschauer H., Kollenz G., Högenauer G., Turnowsky F. Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coli. J Biol Chem. 1994 Feb 25;269(8):5493–5496. [PubMed] [Google Scholar]
  8. Bloom B. R., Murray C. J. Tuberculosis: commentary on a reemergent killer. Science. 1992 Aug 21;257(5073):1055–1064. doi: 10.1126/science.257.5073.1055. [DOI] [PubMed] [Google Scholar]
  9. Chae H. Z., Robison K., Poole L. B., Church G., Storz G., Rhee S. G. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7017–7021. doi: 10.1073/pnas.91.15.7017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cockerill F. R., 3rd, Uhl J. R., Temesgen Z., Zhang Y., Stockman L., Roberts G. D., Williams D. L., Kline B. C. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis. 1995 Jan;171(1):240–245. doi: 10.1093/infdis/171.1.240. [DOI] [PubMed] [Google Scholar]
  11. Cohn D. L., Bustreo F., Raviglione M. C. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis. 1997 Jan;24 (Suppl 1):S121–S130. doi: 10.1093/clinids/24.supplement_1.s121. [DOI] [PubMed] [Google Scholar]
  12. Cole S. T. Mycobacterium tuberculosis: drug-resistance mechanisms. Trends Microbiol. 1994 Oct;2(10):411–415. doi: 10.1016/0966-842x(94)90621-1. [DOI] [PubMed] [Google Scholar]
  13. Cooksey R. C., Morlock G. P., Glickman S., Crawford J. T. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City. J Clin Microbiol. 1997 May;35(5):1281–1283. doi: 10.1128/jcm.35.5.1281-1283.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Davies J., Wright G. D. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol. 1997 Jun;5(6):234–240. doi: 10.1016/S0966-842X(97)01033-0. [DOI] [PubMed] [Google Scholar]
  15. De Beenhouwer H., Lhiang Z., Jannes G., Mijs W., Machtelinckx L., Rossau R., Traore H., Portaels F. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis. 1995 Oct;76(5):425–430. doi: 10.1016/0962-8479(95)90009-8. [DOI] [PubMed] [Google Scholar]
  16. Demple B., Halbrook J. Inducible repair of oxidative DNA damage in Escherichia coli. Nature. 1983 Aug 4;304(5925):466–468. doi: 10.1038/304466a0. [DOI] [PubMed] [Google Scholar]
  17. Deretic V., Philipp W., Dhandayuthapani S., Mudd M. H., Curcic R., Garbe T., Heym B., Via L. E., Cole S. T. Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to isoniazid. Mol Microbiol. 1995 Sep;17(5):889–900. doi: 10.1111/j.1365-2958.1995.mmi_17050889.x. [DOI] [PubMed] [Google Scholar]
  18. Dessen A., Quémard A., Blanchard J. S., Jacobs W. R., Jr, Sacchettini J. C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science. 1995 Mar 17;267(5204):1638–1641. doi: 10.1126/science.7886450. [DOI] [PubMed] [Google Scholar]
  19. Dooley S. W., Jarvis W. R., Martone W. J., Snider D. E., Jr Multidrug-resistant tuberculosis. Ann Intern Med. 1992 Aug 1;117(3):257–259. doi: 10.7326/0003-4819-117-3-257. [DOI] [PubMed] [Google Scholar]
  20. Douglass J., Steyn L. M. A ribosomal gene mutation in streptomycin-resistant Mycobacterium tuberculosis isolates. J Infect Dis. 1993 Jun;167(6):1505–1506. doi: 10.1093/infdis/167.6.1505. [DOI] [PubMed] [Google Scholar]
  21. Edlin B. R., Tokars J. I., Grieco M. H., Crawford J. T., Williams J., Sordillo E. M., Ong K. R., Kilburn J. O., Dooley S. W., Castro K. G. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992 Jun 4;326(23):1514–1521. doi: 10.1056/NEJM199206043262302. [DOI] [PubMed] [Google Scholar]
  22. Felmlee T. A., Liu Q., Whelen A. C., Williams D., Sommer S. S., Persing D. H. Genotypic detection of Mycobacterium tuberculosis rifampin resistance: comparison of single-strand conformation polymorphism and dideoxy fingerprinting. J Clin Microbiol. 1995 Jun;33(6):1617–1623. doi: 10.1128/jcm.33.6.1617-1623.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Finken M., Kirschner P., Meier A., Wrede A., Böttger E. C. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol. 1993 Sep;9(6):1239–1246. doi: 10.1111/j.1365-2958.1993.tb01253.x. [DOI] [PubMed] [Google Scholar]
  24. Frieden T. R., Sterling T., Pablos-Mendez A., Kilburn J. O., Cauthen G. M., Dooley S. W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993 Feb 25;328(8):521–526. doi: 10.1056/NEJM199302253280801. [DOI] [PubMed] [Google Scholar]
  25. Gay J. D., DeYoung D. R., Roberts G. D. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrob Agents Chemother. 1984 Jul;26(1):94–96. doi: 10.1128/aac.26.1.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Gellert M., Mizuuchi K., O'Dea M. H., Nash H. A. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A. 1976 Nov;73(11):3872–3876. doi: 10.1073/pnas.73.11.3872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Gellert M., O'Dea M. H., Itoh T., Tomizawa J. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci U S A. 1976 Dec;73(12):4474–4478. doi: 10.1073/pnas.73.12.4474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Grange J. M. Drug resistance and tuberculosis elimination. Bull Int Union Tuberc Lung Dis. 1990 Jun-Sep;65(2-3):57–59. [PubMed] [Google Scholar]
  29. Heifets L., Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis. 1992 May;145(5):1223–1225. doi: 10.1164/ajrccm/145.5.1223. [DOI] [PubMed] [Google Scholar]
  30. Hewlett D., Jr, Horn D. L., Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA. 1995 Mar 22;273(12):916–917. [PubMed] [Google Scholar]
  31. Heym B., Alzari P. M., Honoré N., Cole S. T. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol. 1995 Jan;15(2):235–245. doi: 10.1111/j.1365-2958.1995.tb02238.x. [DOI] [PubMed] [Google Scholar]
  32. Heym B., Honoré N., Truffot-Pernot C., Banerjee A., Schurra C., Jacobs W. R., Jr, van Embden J. D., Grosset J. H., Cole S. T. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet. 1994 Jul 30;344(8918):293–298. doi: 10.1016/s0140-6736(94)91338-2. [DOI] [PubMed] [Google Scholar]
  33. Heym B., Stavropoulos E., Honoré N., Domenech P., Saint-Joanis B., Wilson T. M., Collins D. M., Colston M. J., Cole S. T. Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun. 1997 Apr;65(4):1395–1401. doi: 10.1128/iai.65.4.1395-1401.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Higgins N. P., Peebles C. L., Sugino A., Cozzarelli N. R. Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1773–1777. doi: 10.1073/pnas.75.4.1773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Honoré N., Cole S. T. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother. 1994 Feb;38(2):238–242. doi: 10.1128/aac.38.2.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Iseman M. D., Madsen L. A. Drug-resistant tuberculosis. Clin Chest Med. 1989 Sep;10(3):341–353. [PubMed] [Google Scholar]
  37. Iseman M. D., Sbarbaro J. A. The increasing prevalence of resistance to antituberculosis chemotherapeutic agents: implications for global tuberculosis control. Curr Clin Top Infect Dis. 1992;12:188–207. [PubMed] [Google Scholar]
  38. Jaber M., Rattan A., Kumar R. Presence of katG gene in resistant Mycobacterium tuberculosis. J Clin Pathol. 1996 Nov;49(11):945–947. doi: 10.1136/jcp.49.11.945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Jin D. J., Gross C. A. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol. 1988 Jul 5;202(1):45–58. doi: 10.1016/0022-2836(88)90517-7. [DOI] [PubMed] [Google Scholar]
  40. Johnsson K., Froland W. A., Schultz P. G. Overexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosis. J Biol Chem. 1997 Jan 31;272(5):2834–2840. doi: 10.1074/jbc.272.5.2834. [DOI] [PubMed] [Google Scholar]
  41. KONNO K., NAGAYAMA H., OKA S. Nicotinamidase in Mycobacteria: a method for distinguishing bovine type tubercle bacilli from other Mycobacteria. Nature. 1959 Nov 28;184(Suppl 22):1743–1744. doi: 10.1038/1841743b0. [DOI] [PubMed] [Google Scholar]
  42. Kapur V., Li L. L., Hamrick M. R., Plikaytis B. B., Shinnick T. M., Telenti A., Jacobs W. R., Jr, Banerjee A., Cole S., Yuen K. Y. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med. 1995 Feb;119(2):131–138. [PubMed] [Google Scholar]
  43. Kapur V., Li L. L., Iordanescu S., Hamrick M. R., Wanger A., Kreiswirth B. N., Musser J. M. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol. 1994 Apr;32(4):1095–1098. doi: 10.1128/jcm.32.4.1095-1098.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Kilburn J. O., Takayama K. Effects of ethambutol on accumulation and secretion of trehalose mycolates and free mycolic acid in Mycobacterium smegmatis. Antimicrob Agents Chemother. 1981 Sep;20(3):401–404. doi: 10.1128/aac.20.3.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Kim B. J., Kim S. Y., Park B. H., Lyu M. A., Park I. K., Bai G. H., Kim S. J., Cha C. Y., Kook Y. H. Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR-single-strand conformation polymorphism analysis for rifampin susceptibility testing. J Clin Microbiol. 1997 Feb;35(2):492–494. doi: 10.1128/jcm.35.2.492-494.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Kirchhausen T., Wang J. C., Harrison S. C. DNA gyrase and its complexes with DNA: direct observation by electron microscopy. Cell. 1985 Jul;41(3):933–943. doi: 10.1016/s0092-8674(85)80074-x. [DOI] [PubMed] [Google Scholar]
  47. Kirkegaard K., Wang J. C. Mapping the topography of DNA wrapped around gyrase by nucleolytic and chemical probing of complexes of unique DNA sequences. Cell. 1981 Mar;23(3):721–729. doi: 10.1016/0092-8674(81)90435-9. [DOI] [PubMed] [Google Scholar]
  48. Kochi A., Vareldzis B., Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol. 1993 Feb;144(2):104–110. doi: 10.1016/0923-2508(93)90023-u. [DOI] [PubMed] [Google Scholar]
  49. Levin M. E., Hatfull G. F. Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Mol Microbiol. 1993 Apr;8(2):277–285. doi: 10.1111/j.1365-2958.1993.tb01572.x. [DOI] [PubMed] [Google Scholar]
  50. Lewis R. J., Tsai F. T., Wigley D. B. Molecular mechanisms of drug inhibition of DNA gyrase. Bioessays. 1996 Aug;18(8):661–671. doi: 10.1002/bies.950180810. [DOI] [PubMed] [Google Scholar]
  51. MIDDLEBROOK G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am Rev Tuberc. 1954 Mar;69(3):471–472. doi: 10.1164/art.1954.69.3.471. [DOI] [PubMed] [Google Scholar]
  52. Mdluli K., Sherman D. R., Hickey M. J., Kreiswirth B. N., Morris S., Stover C. K., Barry C. E., 3rd Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis. 1996 Nov;174(5):1085–1090. doi: 10.1093/infdis/174.5.1085. [DOI] [PubMed] [Google Scholar]
  53. Meier A., Kirschner P., Bange F. C., Vogel U., Böttger E. C. Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother. 1994 Feb;38(2):228–233. doi: 10.1128/aac.38.2.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Morris S., Bai G. H., Suffys P., Portillo-Gomez L., Fairchok M., Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis. 1995 Apr;171(4):954–960. doi: 10.1093/infdis/171.4.954. [DOI] [PubMed] [Google Scholar]
  55. Nair J., Rouse D. A., Bai G. H., Morris S. L. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Microbiol. 1993 Nov;10(3):521–527. doi: 10.1111/j.1365-2958.1993.tb00924.x. [DOI] [PubMed] [Google Scholar]
  56. Ovchinnikov YuA, Monastyrskaya G. S., Gubanov V. V., Lipkin V. M., Sverdlov E. D., Kiver I. F., Bass I. A., Mindlin S. Z., Danilevskaya O. N., Khesin R. B. Primary structure of Escherichia coli RNA polymerase nucleotide substitution in the beta subunit gene of the rifampicin resistant rpoB255 mutant. Mol Gen Genet. 1981;184(3):536–538. doi: 10.1007/BF00352535. [DOI] [PubMed] [Google Scholar]
  57. Ovchinnikov Y. A., Monastyrskaya G. S., Gubanov V. V., Guryev S. O., Chertov OYu, Modyanov N. N., Grinkevich V. A., Makarova I. A., Marchenko T. V., Polovnikova I. N. The primary structure of Escherichia coli RNA polymerase. Nucleotide sequence of the rpoB gene and amino-acid sequence of the beta-subunit. Eur J Biochem. 1981 Jun 1;116(3):621–629. doi: 10.1111/j.1432-1033.1981.tb05381.x. [DOI] [PubMed] [Google Scholar]
  58. Pearson M. L., Jereb J. A., Frieden T. R., Crawford J. T., Davis B. J., Dooley S. W., Jarvis W. R. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med. 1992 Aug 1;117(3):191–196. doi: 10.7326/0003-4819-117-3-191. [DOI] [PubMed] [Google Scholar]
  59. Pretorius G. S., van Helden P. D., Sirgel F., Eisenach K. D., Victor T. C. Mutations in katG gene sequences in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis are rare. Antimicrob Agents Chemother. 1995 Oct;39(10):2276–2281. doi: 10.1128/aac.39.10.2276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Quémard A., Sacchettini J. C., Dessen A., Vilcheze C., Bittman R., Jacobs W. R., Jr, Blanchard J. S. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry. 1995 Jul 4;34(26):8235–8241. doi: 10.1021/bi00026a004. [DOI] [PubMed] [Google Scholar]
  61. Rastogi N., Goh K. S. Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine. Antimicrob Agents Chemother. 1990 Nov;34(11):2061–2064. doi: 10.1128/aac.34.11.2061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Rastogi N., Goh K. S., Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob Agents Chemother. 1992 Dec;36(12):2843–2846. doi: 10.1128/aac.36.12.2843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Reece R. J., Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol. 1991;26(3-4):335–375. doi: 10.3109/10409239109114072. [DOI] [PubMed] [Google Scholar]
  64. Revel V., Cambau E., Jarlier V., Sougakoff W. Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. Antimicrob Agents Chemother. 1994 Sep;38(9):1991–1996. doi: 10.1128/aac.38.9.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Rosner J. L. Susceptibilities of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid. Antimicrob Agents Chemother. 1993 Oct;37(10):2251–2253. doi: 10.1128/aac.37.10.2251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Rouse D. A., DeVito J. A., Li Z., Byer H., Morris S. L. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance. Mol Microbiol. 1996 Nov;22(3):583–592. doi: 10.1046/j.1365-2958.1996.00133.x. [DOI] [PubMed] [Google Scholar]
  67. Rouse D. A., Li Z., Bai G. H., Morris S. L. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Nov;39(11):2472–2477. doi: 10.1128/aac.39.11.2472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Scorpio A., Collins D., Whipple D., Cave D., Bates J., Zhang Y. Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol. 1997 Jan;35(1):106–110. doi: 10.1128/jcm.35.1.106-110.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Scorpio A., Lindholm-Levy P., Heifets L., Gilman R., Siddiqi S., Cynamon M., Zhang Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1997 Mar;41(3):540–543. doi: 10.1128/aac.41.3.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996 Jun;2(6):662–667. doi: 10.1038/nm0696-662. [DOI] [PubMed] [Google Scholar]
  71. Shaila M. S., Gopinathan K. P., Ramakrishnan T. Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains. Antimicrob Agents Chemother. 1973 Sep;4(3):205–213. doi: 10.1128/aac.4.3.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Shen L. L., Pernet A. G. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci U S A. 1985 Jan;82(2):307–311. doi: 10.1073/pnas.82.2.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Sherman D. R., Mdluli K., Hickey M. J., Arain T. M., Morris S. L., Barry C. E., 3rd, Stover C. K. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science. 1996 Jun 14;272(5268):1641–1643. doi: 10.1126/science.272.5268.1641. [DOI] [PubMed] [Google Scholar]
  74. Sherman D. R., Sabo P. J., Hickey M. J., Arain T. M., Mahairas G. G., Yuan Y., Barry C. E., 3rd, Stover C. K. Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria. Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6625–6629. doi: 10.1073/pnas.92.14.6625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Shimao T. Drug resistance in tuberculosis control. Tubercle. 1987 Jun;68(2 Suppl):5–18. doi: 10.1016/0041-3879(87)90014-6. [DOI] [PubMed] [Google Scholar]
  76. Shoeb H. A., Bowman B. U., Jr, Ottolenghi A. C., Merola A. J. Peroxidase-mediated oxidation of isoniazid. Antimicrob Agents Chemother. 1985 Mar;27(3):399–403. doi: 10.1128/aac.27.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Snider D. E., Jr, Roper W. L. The new tuberculosis. N Engl J Med. 1992 Mar 5;326(10):703–705. doi: 10.1056/NEJM199203053261011. [DOI] [PubMed] [Google Scholar]
  78. Spratt B. G. Resistance to antibiotics mediated by target alterations. Science. 1994 Apr 15;264(5157):388–393. doi: 10.1126/science.8153626. [DOI] [PubMed] [Google Scholar]
  79. Sreevatsan S., Pan X., Zhang Y., Deretic V., Musser J. M. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother. 1997 Mar;41(3):600–606. doi: 10.1128/aac.41.3.600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Sreevatsan S., Pan X., Zhang Y., Kreiswirth B. N., Musser J. M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother. 1997 Mar;41(3):636–640. doi: 10.1128/aac.41.3.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Sreevatsan S., Stockbauer K. E., Pan X., Kreiswirth B. N., Moghazeh S. L., Jacobs W. R., Jr, Telenti A., Musser J. M. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother. 1997 Aug;41(8):1677–1681. doi: 10.1128/aac.41.8.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Stoeckle M. Y., Guan L., Riegler N., Weitzman I., Kreiswirth B., Kornblum J., Laraque F., Riley L. W. Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. J Infect Dis. 1993 Oct;168(4):1063–1065. doi: 10.1093/infdis/168.4.1063. [DOI] [PubMed] [Google Scholar]
  83. Takayama K., Armstrong E. L., Kunugi K. A., Kilburn J. O. Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis. Antimicrob Agents Chemother. 1979 Aug;16(2):240–242. doi: 10.1128/aac.16.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Takayama K., Kilburn J. O. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother. 1989 Sep;33(9):1493–1499. doi: 10.1128/aac.33.9.1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Takayama K., Schnoes H. K., Armstrong E. L., Boyle R. W. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J Lipid Res. 1975 Jul;16(4):308–317. [PubMed] [Google Scholar]
  86. Takiff H. E., Salazar L., Guerrero C., Philipp W., Huang W. M., Kreiswirth B., Cole S. T., Jacobs W. R., Jr, Telenti A. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother. 1994 Apr;38(4):773–780. doi: 10.1128/aac.38.4.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M. J., Matter L., Schopfer K., Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993 Mar 13;341(8846):647–650. doi: 10.1016/0140-6736(93)90417-f. [DOI] [PubMed] [Google Scholar]
  88. Telenti A., Imboden P., Marchesi F., Schmidheini T., Bodmer T. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother. 1993 Oct;37(10):2054–2058. doi: 10.1128/aac.37.10.2054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Telenti A., Persing D. H. Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Res Microbiol. 1996 Jan-Feb;147(1-2):73–79. doi: 10.1016/0923-2508(96)80207-5. [DOI] [PubMed] [Google Scholar]
  90. Telenti A., Philipp W. J., Sreevatsan S., Bernasconi C., Stockbauer K. E., Wieles B., Musser J. M., Jacobs W. R., Jr The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med. 1997 May;3(5):567–570. doi: 10.1038/nm0597-567. [DOI] [PubMed] [Google Scholar]
  91. Vareldzis B. P., Grosset J., de Kantor I., Crofton J., Laszlo A., Felten M., Raviglione M. C., Kochi A. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis. 1994 Feb;75(1):1–7. doi: 10.1016/0962-8479(94)90096-5. [DOI] [PubMed] [Google Scholar]
  92. Whelen A. C., Felmlee T. A., Hunt J. M., Williams D. L., Roberts G. D., Stockman L., Persing D. H. Direct genotypic detection of Mycobacterium tuberculosis rifampin resistance in clinical specimens by using single-tube heminested PCR. J Clin Microbiol. 1995 Mar;33(3):556–561. doi: 10.1128/jcm.33.3.556-561.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Williams D. L., Waguespack C., Eisenach K., Crawford J. T., Portaels F., Salfinger M., Nolan C. M., Abe C., Sticht-Groh V., Gillis T. P. Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2380–2386. doi: 10.1128/aac.38.10.2380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Willmott C. J., Critchlow S. E., Eperon I. C., Maxwell A. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol. 1994 Sep 30;242(4):351–363. doi: 10.1006/jmbi.1994.1586. [DOI] [PubMed] [Google Scholar]
  95. Wilson T. M., Collins D. M. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol. 1996 Mar;19(5):1025–1034. doi: 10.1046/j.1365-2958.1996.449980.x. [DOI] [PubMed] [Google Scholar]
  96. Woese C. R., Gutell R. R. Evidence for several higher order structural elements in ribosomal RNA. Proc Natl Acad Sci U S A. 1989 May;86(9):3119–3122. doi: 10.1073/pnas.86.9.3119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Wolucka B. A., McNeil M. R., de Hoffmann E., Chojnacki T., Brennan P. J. Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem. 1994 Sep 16;269(37):23328–23335. [PubMed] [Google Scholar]
  98. Woodley C. L., Kilburn J. O., David H. L., Silcox V. A. Susceptibility of mycobacteria to rifampin. Antimicrob Agents Chemother. 1972 Oct;2(4):245–249. doi: 10.1128/aac.2.4.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Zhang Y., Garbe T., Young D. Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol. 1993 May;8(3):521–524. doi: 10.1111/j.1365-2958.1993.tb01596.x. [DOI] [PubMed] [Google Scholar]
  100. Zhang Y., Heym B., Allen B., Young D., Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992 Aug 13;358(6387):591–593. doi: 10.1038/358591a0. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES